Ustekinuma b for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.
Tessa StraatmijerVince B C BiemansFrank HoentjenNanne K H de BoerAlexander G L BodelierGerard DijkstraWillemijn A van DopJeoffrey J L HaansJeroen M JansenP W Jeroen MaljaarsSander van der MarelBas OldenburgCyriel Y PonsioenMarijn C VisschedijkAnnemarie C de VriesRachel L WestC Janneke van der WoudeMarieke J PierikMarjolijn DuijvesteinAndrea E van der Meulen-de JongPublished in: Journal of Crohn's & colitis (2022)
After 104 weeks of ustekinumab treatment, one-third of CD patients were in corticosteroid-free clinical remission.